[Patients with cancer denied treatment with new expensive drugs].
作者信息
Linné Thomas
机构信息
Onkologiska kliniken, Centralsjukhuset, Karlstad.
出版信息
Lakartidningen. 2012;109(26-28):1298.
PMID:22852261
Abstract
摘要
相似文献
1
[Patients with cancer denied treatment with new expensive drugs].
Lakartidningen. 2012;109(26-28):1298.
2
Approvals in 2016: cost-benefit challenges of new anticancer agents.
Nat Rev Clin Oncol. 2017 Feb 20;14(3):133-134. doi: 10.1038/nrclinonc.2017.12.
3
Drug treatment for melanoma: progress, but who pays?
Med J Aust. 2012 Aug 20;197(4):198-9. doi: 10.5694/mja12.10955.
4
Watchdog set to reject four drugs for kidney cancer on the NHS.
BMJ. 2008 Aug 14;337:a1262. doi: 10.1136/bmj.a1262.
5
Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
Oncologist. 2010;15 Suppl 1:49-57. doi: 10.1634/theoncologist.2010-S1-49.
6
News feature: Costly US anticancer drugs pose problems for doctors and patients.
BMJ. 2008 Jul 14;337(7662):a778. doi: 10.1136/bmj.a778.
7
Cost effectiveness of sunitinib.
J Clin Oncol. 2008 Dec 10;26(35):5829; author reply 5829-30. doi: 10.1200/JCO.2008.19.8101. Epub 2008 Nov 10.
8
Optional copayments on anti-cancer drugs.
BMJ. 2013 Jan 24;346:f349. doi: 10.1136/bmj.f349.
9
Do oncologists believe new cancer drugs offer good value?
Oncologist. 2006 Feb;11(2):90-5. doi: 10.1634/theoncologist.11-2-90.
10
Outpatient cancer drug costs: changes, drivers, and the future.
Cancer. 2002 Feb 15;94(4):1142-50.
Zotero 插件